Şadan Soyyiğit

Şadan Soyyiğit

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2019 in International Archives of Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
RKReşat Kendirlinan
Reşat Kendirlinan
Reyhan GümüşburunReyhan Gümüşburun
Reyhan Gümüşburun
PÇPamir Çerçi
Pamir Çerçi
EÖEmre Özbek
Emre Özbek
SASeda Altıner
Seda Altıner
SBSevim Bavbek
Sevim Bavbek
Background: Rapid drug desensitization (RDD) induces a temporary tolerance to chemotherapeutics that induce hypersensitivity reactions (HSRs). Purpose: Our objective is to report our experience with RDD to platins, taxanes, etoposide, doxorubicin, and irinotecan. Methods: The study was conducted as a retrospective chart review of patients with symptoms of HSRs to chemotherapeutics. HSRs were classified as grade I, II, or III, based on their severity. Skin prick/intradermal tests were performed with implicated chemotherapeutics. A 12-step RDD protocol was used. Results: The study consisted of 38 women and 3 men (mean age 53.3 ± 11.6 years). Patients had ovarian (n = 13, 31.8%), breast (n = 10, 24.4%), colon (n = 7, 17%), lung (n = 4, 9.8%), and other cancers (n = 7; endometrial sarcoma, testicular cancer, uterine cancer, ampulla of Vater tumor, choledochal tumor, peritonitis carcinomatosa, and Merkel cell carcinoma, n = 1, respectively). Twenty-two patients experienced HSRs to platins, 15 to taxanes, and 4 to other chemotherapeutics (doxorubicin, irinotecan, and etoposide). A total of 122 RDDs (47 to platins, 52 to taxanes, 23 to other chemotherapeutics) were performed. In 25 (61%) patients no reactions occurred during RDD, but breakthrough reactions developed in 16 patients (39%) with platins (n = 11), taxanes (n = 3), doxorubicin (n = 1), and irinotecan (n = 1). RDD procedures could not be completed in only 2 patients with grade II breakthrough reactions to carboplatin and oxaliplatin. Conclusion: In our experience, 98.3% of 122 RDDs were completed. We found that RDD was safe and effective in this the largest series of RDD with chemotherapeutics in our country.

31 May 2023 in Journal of Asthma
Verified
Journal Article
Closed access
GCGulfem Elif Celik
Gulfem Elif Celik
OAOmur Aydin
Omur Aydin
DGDerya Gökmen
Derya Gökmen
GBGozde Koycu Buhari
Gozde Koycu Buhari
ZSZeynep Celebi Sözener
Zeynep Celebi Sözener
AYArzu Yorgancioglu
Arzu Yorgancioglu
National data on asthma characteristics and the factors associated with uncontrolled asthma seem to be necessary for every country. For this purpose, we developed the Turkish Adult Asthma Registry ...

1 September 2014 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Closed access
ŞSŞadan Soyyiğit
Şadan Soyyiğit
RKReşat Kendirlinan
Reşat Kendirlinan
OAOmur Aydin
Omur Aydin
GÇGülfem E. Çelik
Gülfem E. Çelik

1 September 2016 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Closed access
ŞSŞadan Soyyiğit
Şadan Soyyiğit
OAOmur Aydin
Omur Aydin
IYİnSu Yılmaz
İnSu Yılmaz
SÖSeçil Kepil Özdemir
Seçil Kepil Özdemir
VCVesile Şentürk Cankorur
Vesile Şentürk Cankorur
GÇGülfem Elif Çelik
Gülfem Elif Çelik

16 February 2025 in Journal of Asthma
Verified
Journal Article
Closed access
ZSZeynep Celebi Sözener
Zeynep Celebi Sözener
IOI.Kivilcim Oguzulgen
I.Kivilcim Oguzulgen
FAFunda Seher Ozalp Ates
Funda Seher Ozalp Ates
ABAyse Baccioglu
Ayse Baccioglu
SBSerap Argun Baris
Serap Argun Baris
GCGulfem Elif Celik
Gulfem Elif Celik
The obese-asthma phenotype has gradually increased in the last few years. We aimed to assess the differences between obese and non-obese patients with asthma. This research is a subanalysis of the Turkish Adult Asthma Registry (TAAR). Clinical presentation, disease control, severity, and demographics of obese and non-obese (lean, normal-weight, overweight) patients were compared. The obesity rate in TAAR was 32.2% (n = 619/1919; 18-83 years; 527 F/92 M). Patients with asthma and obesity had higher rates of childhood obesity, longer symptom duration, later onset of asthma, and more severe asthma. These patients were more likely to be female, older, less educated, and live in rural areas. Patients with obesity had more scheduled visits and emergency visits compared with non-obese patients, but similar asthma control, oral corticosteroid use, hospitalizations, intensive care unit admissions, and unscheduled visits. They also had a higher frequency of T2-high but lower frequency of possible T2-low phenotypes compared with normal-weight asthmatics. The risk of severe asthma in patients with obesity was 6.04 times higher for allergic than non-allergic patients and 3.58 times higher for the T2-high phenotype than for possible T2-low phenotypes. A one-unit increase in the asthma control test reduced the risk of severe asthma by 22%. A good definition of this phenotype is important to ensure that appropriate treatment strategies are implemented to achieve the control goal. We also believe that prevention of childhood obesity is an effective and pivotal strategy to achieve the goal of asthma control.

23 February 2025 in Medicina
Verified
Journal Article
Open access
PDF file
BABegum Gorgulu Akin
Begum Gorgulu Akin
BÖBetül Özdel Öztürk
Betül Özdel Öztürk
MDMakbule seda bayrak durmaz
Makbule seda bayrak durmaz
OAOzge OZTURK AKTAS
Ozge OZTURK AKTAS
ŞSŞadan Soyyiğit
Şadan Soyyiğit
Background and Objectives: Early-type drug hypersensitivity reactions (DHRs) are observed within the first 1–6 h and most commonly manifest as urticaria and/or angioedema. Detailed anamnesis, skin prick tests (SPTs), intradermal tests (IDTs), and oral/intramuscular/intravenous drug provocation tests (DPTs) can be used to identify the drug responsible. We aimed to evaluate the demographic characteristics, responsible drugs, DHR types, and DPT results used in the diagnosis of drug allergy in patients who presented to our clinic with suspected drug allergies. Materials and Methods: The medical records of patients who presented with a suspicion of an early-type DHR between February 2019 and December 2024 were retrospectively evaluated through the hospital information management system. A total of 188 adults who underwent diagnostic drug testing were included. Results: The diagnosis of drug allergy was confirmed in 51 (27%) patients. In 137 (73%) patients, the diagnosis of drug allergy was excluded after DPTs. In 78 of the 188 patients, there was a DHR to a single suspected drug. The other 110 patients had DHR histories with multiple drugs. The rate of confirmation of a drug allergy from diagnostic tests was higher in those who described a history of multiple drug allergies. Amongst the antibiotics, beta-lactam antibiotics (n = 47) were the most frequently suspected drugs. The rate of positive DPTs (n = 4; 8%) was lower in patients with suspected beta-lactam allergies than other antibiotics (p = 0.002). NSAIDs (n = 60) were the second most common group of suspected drug allergies. With regard to IgE or COX-1-mediated mechanisms, there was no statistically significant difference in DPT positivity among these NSAIDs (p = 0.414). The severity of the initial early-type DHRs were grade 1 (n = 168; 80%), grade 2 (n = 14; 7%), and grade 3 (n = 14; 7%). If the patients had redness, itching, urticaria, angioedema, dyspnea, cyanosis, desaturation, syncope, tachycardia, or hypotension during their initial DHRs, the positive diagnostic drug test rate was statistically significantly higher. However, experiencing diarrhea, nausea, and vomiting were not found to be associated with positive diagnostic drug tests. Drug allergies were confirmed with SPTs or IDTs in all patients in whom adrenaline was used during initial reactions. Conclusions: Contrary to the prevailing notion that drugs (especially beta-lactams) are the predominant cause of allergic reactions, this study demonstrated that the actual prevalence of drug allergies is, in fact, low.